(Q47822603)

English

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

scientific article published in July 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Gibson CM

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

Goel M

2

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

Cohen DJ

3

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

Piana RN

4

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

Deckelbaum LI

5

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

Harris KE

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

King SB 3rd

7

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

language of work or name

0 references

publication date

1 July 1998

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

Journal of the American College of Cardiology

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

32

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

28-34

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

Antithrombotic Therapy during Percutaneous Coronary Intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of platelet glycoprotein IIb/IIIa receptors. Will they be useful when given chronically?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New antithrombotics

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New approaches to antiplatelet therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

TIMI frame count: a quantitative method of assessing coronary artery flow

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900192-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0735-1097(98)00192-2

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/9669245

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47822603&oldid=1408840011"